Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.
The current evidence-base for recommendations on the treatment of cutaneous leishmaniasis (CL) is generally weak. Systematic reviews have pointed to a general lack of standardization of methods for the conduct and analysis of clinical trials of CL, compounded with poor overall quality of several tri...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3605149?pdf=render |
id |
doaj-4095eff5c5754f3b90248ec3efdfd325 |
---|---|
record_format |
Article |
spelling |
doaj-4095eff5c5754f3b90248ec3efdfd3252020-11-25T01:36:58ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352013-01-0173e213010.1371/journal.pntd.0002130Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis.Piero OlliaroMichel VaillantByron AranaMax GroglFarrokh ModabberAlan MagillOlivier LapujadePierre BuffetJorge AlvarThe current evidence-base for recommendations on the treatment of cutaneous leishmaniasis (CL) is generally weak. Systematic reviews have pointed to a general lack of standardization of methods for the conduct and analysis of clinical trials of CL, compounded with poor overall quality of several trials. For CL, there is a specific need for methodologies which can be applied generally, while allowing the flexibility needed to cover the diverse forms of the disease. This paper intends to provide clinical investigators with guidance for the design, conduct, analysis and report of clinical trials of treatments for CL, including the definition of measurable, reproducible and clinically-meaningful outcomes. Having unified criteria will help strengthen evidence, optimize investments, and enhance the capacity for high-quality trials. The limited resources available for CL have to be concentrated in clinical studies of excellence that meet international quality standards.http://europepmc.org/articles/PMC3605149?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Piero Olliaro Michel Vaillant Byron Arana Max Grogl Farrokh Modabber Alan Magill Olivier Lapujade Pierre Buffet Jorge Alvar |
spellingShingle |
Piero Olliaro Michel Vaillant Byron Arana Max Grogl Farrokh Modabber Alan Magill Olivier Lapujade Pierre Buffet Jorge Alvar Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Neglected Tropical Diseases |
author_facet |
Piero Olliaro Michel Vaillant Byron Arana Max Grogl Farrokh Modabber Alan Magill Olivier Lapujade Pierre Buffet Jorge Alvar |
author_sort |
Piero Olliaro |
title |
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. |
title_short |
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. |
title_full |
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. |
title_fullStr |
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. |
title_full_unstemmed |
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. |
title_sort |
methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2013-01-01 |
description |
The current evidence-base for recommendations on the treatment of cutaneous leishmaniasis (CL) is generally weak. Systematic reviews have pointed to a general lack of standardization of methods for the conduct and analysis of clinical trials of CL, compounded with poor overall quality of several trials. For CL, there is a specific need for methodologies which can be applied generally, while allowing the flexibility needed to cover the diverse forms of the disease. This paper intends to provide clinical investigators with guidance for the design, conduct, analysis and report of clinical trials of treatments for CL, including the definition of measurable, reproducible and clinically-meaningful outcomes. Having unified criteria will help strengthen evidence, optimize investments, and enhance the capacity for high-quality trials. The limited resources available for CL have to be concentrated in clinical studies of excellence that meet international quality standards. |
url |
http://europepmc.org/articles/PMC3605149?pdf=render |
work_keys_str_mv |
AT pieroolliaro methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT michelvaillant methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT byronarana methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT maxgrogl methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT farrokhmodabber methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT alanmagill methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT olivierlapujade methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT pierrebuffet methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis AT jorgealvar methodologyofclinicaltrialsaimedatassessinginterventionsforcutaneousleishmaniasis |
_version_ |
1725060448205668352 |